Adaptive Biotechnologies ADPT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.3%+12.7pp | 74.2%+14.5pp | 71.8%+13.4pp | 66%+11.3pp | 62.5%+5.5pp | |
| Operating margin | -15.8%+59.8pp | -20.6%+70.2pp | -30.9%+81.8pp | -59%+70.2pp | -75.7%+49.6pp | |
| Net margin | -16.8%+58.0pp | -21.5%+67.6pp | -31.5%+78.6pp | -59.1%+67.4pp | -74.8%+48.4pp | |
| Returns | ||||||
| Return on equity | -24.4%+36.5pp | -28.2%+34.2pp | -37.2%+29.5pp | -57.5%+9.4pp | -61%+0.6pp | |
| Return on invested capital | -13.2%+23.0pp | -15.5%+22.7pp | -20.2%+23.5pp | -31.8%+22.9pp | -36.2%+14.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.2× | 0.5×+0.2× | 0.5×+0.2× | 0.4×+0.1× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 3.4×+0.4× | 3.3×+0.4× | 3.4×-0.1× | 2.8×-1.1× | 2.9×-1.6× | |
| Leverage | ||||||
| Debt-to-equity | 1×-0.2× | 1×-0.1× | 1×0.0× | 1.2×+0.3× | 1.2×+0.3× | |
| Per Share | ||||||
| Book value per share | $1.39+9.0% | $1.44+4.7% | $1.25-17.4% | $1.18-27.9% | $1.28-32.3% | |
| Valuation | ||||||
| Market capitalization | $2.14B+93.6% | $2.48B+180% | $2.28B+202% | $1.62B+203% | $1.1B+137% | |
| Price / sales | 7.2×+1.4× | 9×+4.0× | 9×+4.8× | 7.9×+4.7× | 5.8×+3.2× | |
| Price / book | 9.9×+4.1× | 11.3×+7.0× | 11.1×+7.8× | 9×+6.8× | 5.8×+4.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Adaptive Biotechnologies's profit margins?
- Adaptive Biotechnologies (ADPT) runs a 75.3% gross margin and a -15.8% operating margin, with a -16.8% net margin.
- Where do Adaptive Biotechnologies's ratios come from?
- Every ratio is computed from Adaptive Biotechnologies's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
